US › Healthcare

Evogene (EVGN)

US · Healthcare · Biotechnology

$0.65+21.27%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$334,000

Revenue YoY

-86.3%

Net profit

$-5.9M

Profit YoY

-126.9%

EPS

$-0.61

EPS estimate

$-0.27

Net margin

-1,757.5%

EPS came in at -0.61 against a street estimate of -0.27 — a miss of 125.9%.

Key statistics

Market cap

$5.7M

Forward P/E

0.0

P/B

6.18

Book value

$-0.24

EPS (TTM)

$-2.04

52-week high

$1.50

52-week low

$0.37

50-day MA

$0.55

200-day MA

$0.87

Beta

0.68

Analyst view

Analysts rate Evogene a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $2.15.

Shareholding

Insiders

17.61%

Institutions

4.01%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	3.77%
Jane Street Group LLC	0.15%
XTX Topco Ltd	0.11%
TWO SIGMA SECURITIES, LLC	0.10%
Daytona Street Capital LLC	0.08%
BNP Paribas Arbitrage, SA	0.08%
UBS Group AG	0.05%
Morgan Stanley - Brokerage Accounts	0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Evogene — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.